皮肤黑色素瘤改良病理淋巴结分类系统的开发与验证
改良系统各分组死亡风险持续递增,而当前AJCC系统死亡风险轮廓较杂乱。
要点
- 阳性淋巴结数、临床检测转移和途中转移是独立预后因素。
- 改良淋巴结分类系统各分组死亡风险持续递增,优于AJCC系统。
- 该系统在SEER-18中验证了总生存和病因特异性死亡。
核心结论
- 改良淋巴结分类系统可准确分层皮肤黑色素瘤死亡风险,应考虑用于未来分期系统。
主要发现
- 改良系统各分组HR:N1a 1.83(95%CI 1.76-1.91)、N1b 2.72(95%CI 2.58-2.86)、N2a 3.79(95%CI 3.51-4.08)、N2b 4.56(95%CI 4.22-4.92)、N3a 6.15(95%CI 5.59-6.76)、N3b 8.25(95%CI 7.64-8.91),P<.001。
- 当前AJCC系统HR轮廓较杂乱:N1a 1.83(95%CI 1.76-1.91)、N1b 3.81(95%CI 3.53-4.12)、N1c 2.59(95%CI 2.30-2.93)、N2a 2.71(95%CI 2.56-2.87)、N2b 4.51(95%CI 4.17-4.87)、N2c 3.44(95%CI 2.60-4.55)、N3a 6.06(95%CI 5.51-6.67)、N3b 8.15(95%CI 7.54-8.81)、N3c 6.90(95%CI 5.60-8.49)。
- 排除因微观淋巴结转移接受完成性淋巴结清扫的患者后,改良系统仍能准确分层。
- 新总分期系统较AJCC第8版一致性改善(C统计量0.690 [95%CI 0.689-0.691] vs 0.666 [95%CI 0.666-0.668])。
临床怎么用
- 在临床中可参考改良淋巴结分类系统对皮肤黑色素瘤患者进行更准确的死亡风险分层。
局限性
- 回顾性队列分析,淋巴结清扫范围仅对2012年及以后诊断的患者可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given the evolving patterns of lymph node evaluation for cutaneous melanoma, it is unclear whether the current nodal classification system will continue to accurately reflect prognosis in the modern era. Existing nodal staging for cutaneous melanoma was developed primarily for patients undergoing completion lymph node dissection (CLND) for node-positive disease and does not produce groups with continuously increasing mortality. OBJECTIVE: To develop and validate a modified nodal classification system for cutaneous melanoma. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis included 105 785 patients with cutaneous melanoma undergoing surgery and nodal evaluation from January 1, 2004, to December 31, 2015, in the National Cancer Database. Extent of lymph node dissection was available for patients diagnosed in 2012 and onward. Multivariable models were generated with number of positive lymph nodes modeled using restricted cubic splines. A modified nodal classification system was derived using recursive partitioning analysis (RPA). The proposed lymph node classification system was validated in 85 499 patients from the Surveillance, Epidemiology, and End Results (SEER-18) database. Data were analyzed from April 9, 2020, to May 28, 2021. MAIN OUTCOMES AND MEASURES: Overall survival. RESULTS: Among the 105 785 patients included in the analysis (62 496 men [59.1%]; mean [SD] age, 59.9 [15.5] years), number of positive lymph nodes (hazard ratio [HR] per lymph node for 0 to 2 positive lymph nodes, 2.48 [95% CI, 2.37-2-61; P < .001]; HR per lymph node for ≥3 positive lymph nodes, 1.10 [95% CI 1.07-1.13; P < .001]), clinically detected metastases (HR, 1.35; 95% CI, 1.27-1.42; P < .001), and in-transit metastases (HR, 1.48; 95% CI, 1.34-1.65; P < .001) were independently associated with mortality. An RPA-derived system using these variables demonstrated continuously increasing mortality for each proposed lymph node classification group, with HRs of 1.83 (95% CI, 1.76-1.91) for N1a, 2.72 (95% CI, 2.58-2.86) for N1b, 3.79 (95% CI, 3.51-4.08) for N2a, 4.56 (95% CI, 4.22-4.92) for N2b, 6.15 (95% CI, 5.59-6.76) for N3a, and 8.25 (95% CI, 7.64-8.91) for N3b in the proposed system (P < .001). By contrast, the current American Joint Committee on Cancer (AJCC) nodal classification system produced a more haphazard mortality profile, with HRs of 1.83 (95% CI, 1.76-1.91) for N1a, 3.81 (95% CI, 3.53-4.12) for N1b, 2.59 (95% CI, 2.30-2.93) for N1c, 2.71 (95% CI, 2.56-2.87) for N2a, 4.51 (95% CI, 4.17-4.87) for N2b, 3.44 (95% CI, 2.60-4.55) for N2c, 6.06 (95% CI, 5.51-6.67) for N3a, 8.15 (95% CI, 7.54-8.81) for N3b, and 6.90 (95% CI, 5.60-8.49) for N3c. As a sensitivity analysis, the proposed system continued to accurately stratify patients when excluding those undergoing CLND for microscopic lymph node metastases. This system was validated for overall survival and cause-specific mortality in SEER-18. Last, a new overall staging system for node-positive patients was developed by RPA and demonstrated improved concordance vs the AJCC, 8th edition system (C statistic, 0.690 [95% CI, 0.689-0.691] vs 0.666 [95% CI, 0.666-0.668]). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that a modified nodal classification system can accurately stratify mortality risk in cutaneous melanoma in an era of increasing use of sentinel lymph node biopsy without CLND and should be considered for future staging systems.
引用
- Nguyen AT, Luu M, Nguyen VP, et al. Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. JAMA Surg. 2021. PMID: 34468697. doi:10.1001/jamasurg.2021.4298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。